• Rapamycin (Sirolimus) and the Next Frontier of mTOR Inhib...

  2025-10-22

  This thought-leadership article bridges cutting-edge mechanistic understanding with actionable strategies for translational researchers leveraging Rapamycin (Sirolimus) in cancer, immunology, and mitochondrial disease models. Through an integration of recent evidence—including emerging resistance pathways such as TFEB-mediated PD-L1 upregulation—this piece charts a strategic roadmap for overcoming current limitations and unlocking the full translational potential of specific mTOR inhibition.

• Gap19: Selective Connexin 43 Hemichannel Blocker in Neuro...

  2025-10-21

  Gap19 enables targeted modulation of neuroglial and inflammatory pathways by selectively inhibiting Cx43 hemichannels without affecting gap junction channels. Its robust performance in cerebral ischemia, ATP release blockade, and macrophage polarization research sets it apart as a gold-standard tool for translational neuroscience and vascular inflammation studies.

77 records 6/6 page Previous First page 上5页 6